



Table S9. Binding amino acids of sites of significant biotargets for novel compounds with anxiolytic activity.

11-substituted 2,3,4,5-tetrahydro-11H-[1,3]diazepino[1,2-a]benzimidazoles of the DAB series


Alpha-1B adrenergic receptor ADRA1B




ADRA1B-DAB-0019



ADRA1B-DAB-0020




ADRA1B-DAB-0021




ADRA1B-DAB-0023


Alpha-2A adrenergic receptor ADRA2A




ADRA2A-DAB-0019



ADRA2A-DAB-0020




ADRA2A-DAB-0021




ADRA2A-DAB-0023


Type-1 angiotensin II receptor AGTR1




AGTR1-DAB-0019



AGTR1-DAB-0020




AGTR1-DAB-0021




AGTR1-DAB-0023


NMDA receptor GluN1/GluN2A/GluN2B GRIN1/GRIN2A/GRIN2B




NMDA-Glut-DAB-0019



NMDA-Glut-DAB-0020




NMDA-Glut-DAB-0021




NMDA-Glut-DAB-0023

3,6-disubstituted [1,2,4]triazolo[3,4-a][2,3]benzodiazepines of the RD series


Alpha-1B adrenergic receptor ADRA1B




ADRA1B-RD-0004



ADRA1B-RD-0012




ADRA1B-RD-0013




ADRA1B-RD-0014


Alpha-2A adrenergic receptor ADRA2A




ADRA2A-RD-0004



ADRA2A-RD-0012




ADRA2A-RD-0013




ADRA2A-RD-0014


Type-1 angiotensin II receptor AGTR1




AGTR1-RD-0004



AGTR1-RD-0012




AGTR1-RD-0013




AGTR1-RD-0014


NMDA receptor GluN1/GluN2A/GluN2B GRIN1/GRIN2A/GRIN2B




NMDA-Glut-RD-0004



NMDA-Glut-RD-0012



NMDA-Glut-RD-0013



NMDA-Glut-RD-0014